We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Chemotherapy May Paradoxically Trigger Future Cancer

By Biotechdaily staff writers
Posted on 23 May 2002
Research has revealed that some drugs used in chemotherapy may actually cause conditions that can lead to the future growth of a cancerous tumor.

Chemotherapy drugs work by interfering with the ability of cancer cells to divide and reproduce themselves. More...
The affected cells become damaged and eventually die. As the drugs are carried in the blood, they can reach cancer cells all over the body. Chemotherapy has to be carefully planned so that it progressively destroys the cancer during the course of treatment but not the normal cells and tissues.

Prof. Batsheva Kerem of the Hebrew University of Jerusalem (Jerusalem, Israel) and colleagues have been studying the chromosomes in cancer cells. They found that cancer cell chromosomes break recurrently at specific regions known as "fragile sites,” sites where the mechanism responsible for DNA replication is disturbed. This could lead to breakage resulting in multiple rearrangements of the chromosomes, a striking characteristic of cancer cells.

Now the researchers report that normal cells also develop fragile regions when they are exposed to certain conditions. Some of the drugs used in chemotherapy may cause these conditions and thus plant the seeds of a future cancerous growth at the same time they are killing the current one. There are some 100 fragile sites in the human genome and five of these sites are now being studied. These findings were reported in the inaugural edition of Cancer Cell, published February 26, 2002.

The researchers say this work creates a better understanding of how chemotherapy drugs work, which will help guide the development of a new generation of drugs designed to halt the growth of cancer cells without inducing fragile sites in normal cells.




Related Links:
The Hebrew University of Jerusalem

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.